{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["103(22)"],"submitter":["Li X"],"pubmed_abstract":["<h4>Background</h4>Previous studies explored the prognostic value of pretreatment platelet count, fibrinogen, and d-dimer level in patients with several types of cancer, however, a comprehensive conclusion has not been reached in osteosarcoma patients.<h4>Methods</h4>PubMed, Web of Science, Embase, and CNKI databases were systematically searched for eligible studies up to May 09, 2023, and pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the prognostic impact of these indicators in osteosarcoma patients.<h4>Results</h4>Twelve studies from China consisting of 1682 patients were finally included. Our findings revealed that an elevated level of pretreatment platelet or d-dimer was associated with a worse outcome of overall survival (platelet: HR = 1.63, 95% CI: 1.18-2.26, P = .003; d-dimer: HR = 2.29, 95% CI: 1.58-3.31, P < .001).<h4>Conclusion</h4>Based on current evidence, pretreatment platelet count and d-dimer level could be good prognostic biomarkers for Chinese osteosarcoma patients. However, future validation is also needed."],"journal":["Medicine"],"pagination":["e38463"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11142833"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic value of pretreatment platelet count, fibrinogen and d-dimer levels in osteosarcoma patients: A meta-analysis."],"pmcid":["PMC11142833"],"pubmed_authors":["Ren H","Li X","Li J","Peng L"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic value of pretreatment platelet count, fibrinogen and d-dimer levels in osteosarcoma patients: A meta-analysis.","description":"<h4>Background</h4>Previous studies explored the prognostic value of pretreatment platelet count, fibrinogen, and d-dimer level in patients with several types of cancer, however, a comprehensive conclusion has not been reached in osteosarcoma patients.<h4>Methods</h4>PubMed, Web of Science, Embase, and CNKI databases were systematically searched for eligible studies up to May 09, 2023, and pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the prognostic impact of these indicators in osteosarcoma patients.<h4>Results</h4>Twelve studies from China consisting of 1682 patients were finally included. Our findings revealed that an elevated level of pretreatment platelet or d-dimer was associated with a worse outcome of overall survival (platelet: HR = 1.63, 95% CI: 1.18-2.26, P = .003; d-dimer: HR = 2.29, 95% CI: 1.58-3.31, P < .001).<h4>Conclusion</h4>Based on current evidence, pretreatment platelet count and d-dimer level could be good prognostic biomarkers for Chinese osteosarcoma patients. However, future validation is also needed.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-03-27T16:34:45.442Z","creation":"2025-08-27T03:08:38.327Z"},"accession":"S-EPMC11142833","cross_references":{"pubmed":["39259059"],"doi":["10.1097/MD.0000000000038463"]}}